Tyro Capital Management LLC increased its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 20.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,108,283 shares of the company's stock after buying an additional 353,307 shares during the period. Roivant Sciences accounts for approximately 8.2% of Tyro Capital Management LLC's investment portfolio, making the stock its 6th biggest holding. Tyro Capital Management LLC owned about 0.29% of Roivant Sciences worth $24,941,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in ROIV. Russell Investments Group Ltd. grew its stake in Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after acquiring an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in shares of Roivant Sciences during the fourth quarter worth approximately $39,000. PNC Financial Services Group Inc. lifted its holdings in shares of Roivant Sciences by 27.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after purchasing an additional 1,507 shares in the last quarter. Wells Fargo & Company MN grew its position in Roivant Sciences by 84.1% in the 4th quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock valued at $89,000 after purchasing an additional 3,426 shares during the period. Finally, Blue Trust Inc. increased its stake in Roivant Sciences by 550.1% during the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company's stock valued at $91,000 after purchasing an additional 6,667 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on ROIV shares. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Monday, April 21st.
Get Our Latest Stock Analysis on ROIV
Roivant Sciences Trading Down 1.1%
Roivant Sciences stock traded down $0.12 during trading on Friday, hitting $10.83. 870,372 shares of the company were exchanged, compared to its average volume of 5,566,740. The business's 50 day moving average is $10.53 and its 200 day moving average is $11.06. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $13.06. The company has a market capitalization of $7.72 billion, a P/E ratio of -72.23 and a beta of 1.23.
Insider Buying and Selling at Roivant Sciences
In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 273,959 shares of the company's stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $11.47, for a total value of $3,142,309.73. Following the completion of the transaction, the insider now owns 39,799,611 shares in the company, valued at $456,501,538.17. This represents a 0.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eric Venker sold 434,478 shares of the firm's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $10.82, for a total value of $4,701,051.96. Following the sale, the chief operating officer now directly owns 1,127,290 shares of the company's stock, valued at approximately $12,197,277.80. This represents a 27.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,223,959 shares of company stock worth $13,450,035. Corporate insiders own 7.90% of the company's stock.
Roivant Sciences Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
See Also
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
